A quiet analytical research laboratory at night, racks of glass vials along a dim bench.

Injection Burden

Most peptides and biologics are injected because no other route delivers enough intact drug. Injections work, but they carry costs in fear, adherence, cold chain, sharps disposal and clinic time, which is why needle-free delivery is one of the most pursued goals in pharmaceutical development.

What injections cost

Needle fear is common: a systematic review found it in a substantial share of adults, with some avoiding care because of it. Injectables require sterile manufacture, often refrigeration, trained administration or patient training, and sharps disposal. For chronic therapies, discontinuation rises with dosing burden. Weekly injectable incretins reduced this burden compared with daily dosing, and patient preference drove development of an oral form. These costs fall on patients, clinics and payers alike.

Realistic alternatives today

Oral delivery with permeation enhancers is approved for semaglutide and octreotide, at the cost of high doses and low bioavailability. Intranasal delivery is approved for several peptides and small molecules. Long-acting injectables reduce frequency rather than eliminate needles. Microneedle patches are in clinical development for vaccines and peptides. Non-peptide oral agonists are a chemistry solution rather than a delivery one. Each alternative trades one limitation for another, usually dose, cost or variability.

What this means for partners

Replacing an injection requires the new route to deliver consistent exposure at an acceptable dose and cost. For most peptides this is not yet possible, and partners should budget for a full development program, including bridging pharmacokinetic studies against the injected reference. Feasibility screening should compare candidate routes early, since the lowest-barrier route that meets the target exposure is usually faster and cheaper to develop than an oral form, and it may be sufficient.

Key facts

Needle fear affects a substantial proportion of adults and is associated with avoidance of vaccination (McLenon and Rogers 2019, J Adv Nurs)
Oral semaglutide was the first oral GLP-1 receptor agonist approved, with bioavailability of about 0.4 to 1% (FDA label, Rybelsus 2019)
Microneedles can deliver drugs and vaccines through the skin with minimal pain (Prausnitz 2004, Adv Drug Deliv Rev)
Oral peptide therapeutics remain limited to a few approved products with low bioavailability (Drucker 2020, Nat Rev Drug Discov)

How our delivery technology applies

We see encapsulation as a contributor to needle-free delivery, not a replacement for injections today. Its role is in routes with lower barriers: buccal and sublingual films with mucoadhesive layers, intranasal formulations with protease shielding, and topical cosmetic peptides. For oral peptides, layered shielding plus a co-released enhancer is a research question in our Peptide Delivery Program, with results reported whether positive or not.

Discuss a needle-free route assessment for your peptide.